These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 34775216)

  • 1. Effect of epidermal growth factor receptor gene mutation on the prognosis of pathological stage II-IIIA (8th edition TNM classification) primary lung cancer after curative surgery.
    Isaka T; Ito H; Nakayama H; Yokose T; Saito H; Adachi H; Miura J; Shigefuku S; Kikuchi A; Rino Y
    Lung Cancer; 2021 Dec; 162():128-134. PubMed ID: 34775216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of epidermal growth factor receptor mutation on early-stage non-small cell lung cancer according to the 8th TNM classification.
    Isaka T; Ito H; Nakayama H; Yokose T; Yamada K; Masuda M
    Lung Cancer; 2020 Jul; 145():111-118. PubMed ID: 32428800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status.
    Isaka T; Ito H; Yokose T; Saito H; Adachi H; Murakami K; Miura J; Kikunishi N; Rino Y
    BMC Cancer; 2022 Sep; 22(1):966. PubMed ID: 36085020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery.
    Isaka T; Nakayama H; Ito H; Yokose T; Yamada K; Masuda M
    BMC Cancer; 2018 Oct; 18(1):959. PubMed ID: 30290774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma.
    Takamochi K; Oh S; Matsunaga T; Suzuki K
    J Thorac Cardiovasc Surg; 2017 Nov; 154(5):1768-1774.e1. PubMed ID: 28826599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy.
    Yang H; Wang K; Li S; Li Y; Yuan L
    Pathol Oncol Res; 2021; 27():1609898. PubMed ID: 34447289
    [No Abstract]   [Full Text] [Related]  

  • 7. Incorporation of EGFR mutation status into M descriptor of new TNM classification influences survival curves in non-small cell lung cancer patients.
    Stanic K; Turnsek N; Vrankar M
    Radiol Oncol; 2019 Nov; 53(4):453-458. PubMed ID: 31747381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic value of AJCC TNM Staging 7th edition in limited-stage small cell lung cancer: validation in 437 patients].
    Zhang W; Zhu H; Zhou Z; Feng Q; Chen D; Zhang H; Xiao Z; Wang L
    Zhonghua Zhong Liu Za Zhi; 2015 Dec; 37(12):917-22. PubMed ID: 26887621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Platinum-Based Adjuvant Chemotherapy on Prognosis of Pathological Stage II/III Lung Adenocarcinoma based on EGFR Mutation Status: A Propensity Score Matching Analysis.
    Isaka T; Ito H; Nakayama H; Yokose T; Katayama K; Yamada K; Masuda M
    Mol Diagn Ther; 2019 Oct; 23(5):657-665. PubMed ID: 31347029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
    Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
    Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC.
    Jung HA; Lim J; Choi YL; Lee SH; Joung JG; Jeon YJ; Choi JW; Shin S; Cho JH; Kim HK; Choi YS; Zo JI; Shim YM; Park S; Sun JM; Ahn JS; Ahn MJ; Han J; Park WY; Kim J; Park K
    Clin Cancer Res; 2022 Oct; 28(19):4312-4321. PubMed ID: 35838647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of RBM10 and PD-L1 expression on the prognosis of pathologic N1-N2 epidermal growth factor receptor mutant lung adenocarcinoma.
    Isaka T; Miyagi Y; Yokose T; Saito H; Kasajima R; Watabe K; Shigeta N; Kikunishi N; Shigefuku S; Murakami K; Adachi H; Nagashima T; Ito H
    Transl Lung Cancer Res; 2023 Oct; 12(10):2001-2014. PubMed ID: 38025811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of the 7th and 8th editions of the AJCC staging system in terms of predicting recurrence and survival in patients with papillary thyroid carcinoma.
    Nam SH; Bae MR; Roh JL; Gong G; Cho KJ; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2018 Dec; 87():158-164. PubMed ID: 30527232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic influence of epidermal growth factor receptor mutation and radiological ground glass appearance in patients with early-stage lung adenocarcinoma.
    Aokage K; Miyoshi T; Wakabayashi M; Ikeno T; Suzuki J; Tane K; Samejima J; Tsuboi M
    Lung Cancer; 2021 Oct; 160():8-16. PubMed ID: 34365179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Clinical Stage I Lung Adenocarcinoma.
    Yang F; Sun K; Li F; Li X; Shi J; Sun X; Hong Y; Jiang G; Zhu Y; Song X
    Ann Thorac Surg; 2024 Jun; 117(6):1111-1119. PubMed ID: 37353101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Significance of the Maximum Standardized Uptake Value on the Prognosis of Clinical Stage IA Lung Adenocarcinoma Based on the 8th Edition TNM Classification.
    Shigefuku S; Ito H; Miura J; Kikuchi A; Isaka T; Adachi H; Nakayama H; Ikeda N
    Ann Surg Oncol; 2023 Feb; 30(2):830-838. PubMed ID: 36282457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic impact of lung adenocarcinoma predominance classification relating to pathological factors in lobectomy, the Japanese Joint Committee of Lung Cancer Registry Database in 2010.
    Ito H; Date H; Shintani Y; Miyaoka E; Nakanishi R; Kadokura M; Endo S; Chida M; Yoshino I; Suzuki H;
    BMC Cancer; 2022 Aug; 22(1):875. PubMed ID: 35948946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?
    Lv C; An C; Feng Q; Ma Y; Li S; Wang J; Zhang J; Wang X; Yan S; Fang J; Wang Y; Tan F; Yang Y
    Clin Lung Cancer; 2015 Nov; 16(6):e173-81. PubMed ID: 25958850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proposal on incorporating lymphovascular invasion as a T-descriptor for stage I lung cancer.
    Wang S; Zhang B; Qian J; Qiao R; Xu J; Zhang L; Zhao Y; Zhang Y; Wang R; Zhao R; Han B
    Lung Cancer; 2018 Nov; 125():245-252. PubMed ID: 30429028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognosis of epidermal growth factor receptor-mutated stage I lung adenocarcinoma with radiologically solid features.
    Hattori A; Matsunaga T; Fukui M; Takamochi K; Suzuki K
    Eur J Cardiothorac Surg; 2022 Mar; 61(4):769-777. PubMed ID: 34791156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.